On March 20, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported that preclinical data for the Company’s anti-PD-L1 monoclonal antibody, has been selected for presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, to be held April 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C (Press release, TG Therapeutics, MAR 20, 2017, View Source [SID1234518216]). Schedule your 30 min Free 1stOncology Demo! The presentation details are as follows:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
• Title: Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301
Abstract Number: 4606
Date and Time: Tuesday, April 4, 2017, 1:00 PM – 5:00 PM ET
Session: Immunoconjugates and Antibodies
Location: Halls A-C, Poster Section 26
Poster Number: 21
A copy of the above referenced abstract can be viewed online through the AACR (Free AACR Whitepaper) meeting website at www.aacr.org. Following the presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.